Our response to COVID-19

We're supporting people to maintain their wellbeing and manage isolation.

Topics tagged with "Schizophrenia and substance use"

Treatments for dual diagnosis

What is dual diagnosis? Dual diagnosis is the term used for people with both mental health and substance use disorders. Studies targeting this population often investigate outcomes relating to both diagnoses, such as symptoms, substance use, social function, quality of life, and cognitive outcomes. What is the evidence for treatments for dual diagnosis? Moderate to low quality evidence suggests olanzapine was superior to perphenazine, quetiapine, risperidone, and ziprasidone for overall symptoms in people with a dual diagnosis. Olanzapine was superior to perphenazine, quetiapine, and ziprasidone for positive symptoms, and olanzapine was superior to perphenazine, risperidone, and ziprasidone for negative symptoms….

Therapies for dual diagnosis

What is dual diagnosis? Dual diagnosis is a term that refers to having both a mental illness and a substance abuse problem. Studies of dual diagnosis investigate the effectiveness and availability of treatments for improving outcomes relating to either diagnosis, such as symptoms, functioning, quality of life, substance use, or cognitive problems. What is the evidence for the effectiveness of therapy for dual diagnosis? Moderate quality evidence suggests a medium-sized benefit of motivational interviewing with or without cognitive behavioural therapy for reducing the amount of cannabis used, but no benefit for reducing frequency of cannabis use. There may also be…

Anticraving agents

What are adjunctive anticraving medications? Anticraving medications includes naltrexone (an opioid receptor antagonist), which aims to reduce craving for and use of substances. What is the evidence for anticraving medications? Low quality evidence is unclear as to the benefit of anticraving agents such as naltrexone for improving substance dependence in people with schizophrenia. September 2020

Substance use

How is substance use related to schizophrenia? Various lines of evidence suggest an association between substance use and psychosis. Experimental studies and surveys of users provide evidence that cannabis and amphetamine use can produce transient, and usually mild, psychotic experiences or recurrence of psychotic symptoms in individuals with a history of psychosis. Further, neuroimaging studies have found clear similarities between functional networks impaired by cannabis use and those known to be implicated in the pathogenesis of schizophrenia. What is the evidence for substance use as a risk factor for schizophrenia? Tobacco Moderate quality evidence finds a small to medium-sized increased…

Drug and alcohol use

What is comorbid drug and alcohol use?  Drug and alcohol misuse, abuse or dependence are concerns for people with schizophrenia due to the association with poor clinical and social outcomes, including high rates of suicide, HIV, homelessness, aggression and incarceration. Moreover, substance use places additional burden on patients, families, psychiatric services, and government resources due to high rates of treatment non-adherence and relapse. This topic covers outcomes for people with schizophrenia and comorbid substance use (termed ‘dual diagnosis’). What is the evidence on outcomes for people with schizophrenia and comorbid drug and alcohol use? High quality evidence shows a small…

Drug and alcohol use

How is drug and alcohol use related to schizophrenia?  Drug and alcohol use, abuse or dependence are concerns due to the association with high rates of suicide, HIV, homelessness, aggression and incarceration. Moreover, comorbid substance use places additional burden on patients, families, psychiatric services, and government resources due to high rates of treatment non-adherence and relapse. What is the evidence for comorbid drug and alcohol use? Moderate quality evidence shows the lifetime prevalence of any illicit drug misuse, abuse or dependence in people with schizophrenia ranges between 17% for those in rehabilitation and long-term settings, to 70% in community health…

NeuRA Libraries

Title Colour Legend:
Green - Topic summary is available.
Orange - Topic summary is being compiled.
Red - Topic summary has no current systematic review available.